Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for β-thalassemia major

被引:43
作者
Aker, M
Kapelushnik, J
Pugatsch, T
Naparstek, E
Ben-Neria, S
Yehuda, O
Amar, A
Nagler, A
Slavin, S
Or, R
机构
[1] Hadassah Univ Hosp, Dept Bone Marrow Transplantat, IL-91120 Jerusalem, Israel
[2] Hadassah Univ Hosp, Dept Pediat, IL-91120 Jerusalem, Israel
[3] Hadassah Univ Hosp, Dept Human Genet, IL-91120 Jerusalem, Israel
[4] Hadassah Univ Hosp, Tissue Typing Unit, IL-91120 Jerusalem, Israel
关键词
beta-thalassemia major; bone marrow transplantation; donor lymphocyte infusion;
D O I
10.1097/00043426-199803000-00011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Donor lymphocyte infusion (DLI) was used to reverse relapse after allogeneic bone marrow transplantation (BMT) in a patient with beta-thalassemia major. Patients and Methods: The patient with unstable mixed chimerism after BMT was treated with graded increments of donor lymphocytes (10(5) T cells/kg to 5x10(7) T cells/kg) to displace residual hematopoietic host cells. Results: DLI resulted in complete donor-derived reconstitution of the hematopoietic compartment. The patient developed mild graft-versus-host disease (GVHD) that could be controlled by steroid treatment. Conclusions: This case report shows that DLI can effectively eradicate host stem cells in mixed chimeras after BMT in nonmalignant hematopoietic diseases.
引用
收藏
页码:145 / 148
页数:4
相关论文
共 18 条
[1]  
BERTHEAS MF, 1991, BLOOD, V78, P3103
[2]   Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [J].
Collins, RH ;
Shpilberg, O ;
Drobyski, WR ;
Porter, DL ;
Giralt, S ;
Champlin, R ;
Goodman, SA ;
Wolff, SN ;
Hu, W ;
Verfaillie, C ;
List, A ;
Dalton, W ;
Ognoskie, N ;
Chetrit, A ;
Antin, JH ;
Nemunaitis, J .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :433-444
[3]  
DROBYSKI WR, 1992, BONE MARROW TRANSPL, V10, P301
[4]  
DROBYSKI WR, 1993, BLOOD, V82, P2310
[5]  
FRASSONI F, 1990, BONE MARROW TRANSPL, V5, P235
[6]  
Kapelushnik J, 1996, BONE MARROW TRANSPL, V18, P1153
[7]   ANALYSIS OF BETA-GLOBIN MUTATIONS SHOWS STABLE MIXED CHIMERISM IN PATIENTS WITH THALASSEMIA AFTER BONE-MARROW TRANSPLANTATION [J].
KAPELUSHNIK, J ;
OR, R ;
FILON, D ;
NAGLER, A ;
CIVIDALLI, G ;
AKER, M ;
NAPARSTEK, E ;
SLAVIN, S ;
OPPENHEIM, A .
BLOOD, 1995, 86 (08) :3241-3246
[8]   DONOR LEUKOCYTE TRANSFUSIONS FOR TREATMENT OF RECURRENT CHRONIC MYELOGENOUS LEUKEMIA IN MARROW TRANSPLANT PATIENTS [J].
KOLB, HJ ;
MITTERMULLER, J ;
CLEMM, C ;
HOLLER, E ;
LEDDEROSE, G ;
BREHM, G ;
HEIM, M ;
WILMANNS, W .
BLOOD, 1990, 76 (12) :2462-2465
[9]   MARROW TRANSPLANTATION IN PATIENTS WITH THALASSEMIA RESPONSIVE TO IRON CHELATION-THERAPY [J].
LUCARELLI, G ;
GALIMBERTI, M ;
POLCHI, P ;
ANGELUCCI, E ;
BARONCIANI, D ;
GIARDINI, C ;
ANDREANI, M ;
AGOSTINELLI, F ;
ALBERTINI, F ;
CLIFT, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (12) :840-844
[10]   Marrow transplantation for patients with thalassemia: Results in class 3 patients [J].
Lucarelli, G ;
Clift, RA ;
Galimberti, M ;
Polchi, P ;
Angelucci, E ;
Baronciani, D ;
Giardini, C ;
Andreani, M ;
Manna, M ;
Nesci, S ;
Agostinelli, F ;
Rapa, S ;
Ripalti, M ;
Albertini, F .
BLOOD, 1996, 87 (05) :2082-2088